BIOGEN INC. — Director's Dealing 2018

Feb 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2018-02-12

Reporting Person: McKenzie Paul (EVP Pharmaceutical Oper & Tech)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-12	Restricted Stock Unit	$0	A	3790	Acquired	2020-02-12	Common Stock (3790)	Direct
2018-02-12	Restricted Stock Unit	$0	A	9470	Acquired	2021-02-12	Common Stock (9470)	Direct

Footnotes

F1: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date.

F2: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).